

Optimizing Gestational Hypertension Treatment Using Central Blood Pressure

Combining central blood pressure with brachial measurements improves risk assessment for women with hypertensive disorders of pregnancy

Executive Summary

- Hypertensive disorders of pregnancy occur in 1 in every 12 to 17 pregnancies. Approximately 25% of cases of gestational hypertension progress to preeclampsia. Proactive identification of populations at risk of preeclampsia is a necessary part of pregnancy management.
- Elevated central aortic pressure predicts preeclampsia. Elevated central aortic pressure appears to be more sensitive in assessing the risk of preeclampsia compared to brachial pressure. Brachial and central aortic pressures provide complimentary information for risk prediction and management decisions.
- Measurements of central arterial pressures can be incorporated into the current approaches to hypertension management as the dual arterial pressure SphygmoCor XCEL device, the only FDA cleared medical device for non-invasive central arterial pressure waveform analysis for all adults, can provide both brachial and central aortic pressures at the same time.
- Incorporation of central aortic blood pressure (BP) monitoring into the treatment paradigm for hypertensive disorders of pregnancy can be utilized as follows: (a) confirmation of hypertension so that initiation of medication is more likely to be the appropriate decision for a patient, (b) avoiding initiation of medication in case of white coat hypertension, (c) avoiding up-titration of medication if not necessary, and (d) confirming when down-titration of medication is needed to avoid overtreatment.
- Based on current technology, the availability of a non-invasive dual arterial pressure measurement system, the compelling clinical rationale and the clinical published research, incorporation of central aortic pressure monitoring should be a part of the care of all pregnant women.

Background

Hypertensive disorders of pregnancy are relatively common, occurring in 1 in every 12 to 17 pregnancies among women ages 20 to 44.¹ Hypertension in pregnancy can be categorized as follows:

1. Chronic Hypertension

Hypertension prior to pregnancy or before 20 weeks of pregnancy. Women who have chronic hypertension may develop preeclampsia in the second or third trimester of pregnancy.²

2. Gestational Hypertension

Hypertension during pregnancy without proteinuria, other renal disorders, biochemical or hematologic disorders or cardiac dysfunction. It is typically diagnosed after 20 weeks of pregnancy or close to delivery. Gestational hypertension usually resolves soon after birth of the child. However, some women with gestational hypertension have a higher risk of developing chronic hypertension in the future. Approximately 25% of gestation hypertension cases progress to preeclampsia.^{2,3}

3. Preeclampsia/Eclampsia

The condition whereby a woman who previously had normal BP develops hypertension or worsening of hypertension in case of chronic hypertension (superimposed preeclampsia) in conjunction with protein in the urine and/or other maternal end-organ dysfunction after 20 weeks of pregnancy. Associated findings may include acute kidney injury, liver dysfunction, neurological features, hemolysis or thrombocytopenia and fetal growth restriction. Preeclampsia occurs in approximately 1 in 25 pregnancies in the United States.^{2,3} Women with preeclampsia may develop eclampsia, which is defined by the new onset of seizures and/or coma. It is estimated that preeclampsia is responsible for >500,000 fetal and neonatal deaths and >70,000 maternal deaths globally.⁴ It is noteworthy that the incidence of preeclampsia has increased by 25% in the last two decades in the US. Importantly, afflicted women have increased cardiovascular risk later in life; specifically, women with a history of preeclampsia have i) a 3.7-fold increased risk of chronic hypertension within 10 years postpartum, with the risk increasing according to the severity of preeclampsia (>3.5-fold after mild preeclampsia, and >6-fold after severe preeclampsia), ii) increased risk of premature cardiovascular disease with a relative risk of 2.0 for mild preeclampsia and up to 9.5 for severe preeclampsia.⁵⁻⁸

Hypertensive disorders of pregnancy are relatively common and occur in 1 out of every 12 to 17 pregnancies among women ages 20 to 44.¹ Approximately 25% progress to preeclampsia.^{2,3}

Diagnosis

Diagnosis is based on standard brachial artery BP measurement, which is the standard of care during pregnancy. Office based BP is generally measured during each prenatal visit. Home BP monitoring as well as 24-hour ambulatory BP monitoring are useful adjuncts in diagnosis and are particularly useful to rule out white coat hypertension (in-office blood pressure measurements elevated relative to home-based readings)). Proteinuria is defined as ≥ 300 mg per 24-hour urine collection, or urine protein/creatinine ratio of ≥ 0.3 mg/dL (>30 mg/mmol) in a spot (random) urine sample, or dipstick reading of 2+ (used only if other quantitative methods are not available or for screening).

Management

Management includes close follow-up and home-based BP monitoring. BP monitoring equipment ideally should have been validated in pregnant women by the manufacturer, although equipment is used without such validation. Pharmacotherapy is used to lower BP to acceptable targets. BP target should be systolic of 110 to 140 mm Hg and diastolic of 85 mm Hg.⁹ The choice of pharmacologic agents in pregnant women differs from standard hypertension management. Acceptable agents include oral methyldopa, labetalol, oxprenolol, and nifedipine.⁹ The American College of Obstetricians and Gynecologists recommends that women with high risk factors for preeclampsia should be treated with low dose acetylsalicylic acid (ASA, aspirin) 81 mg between, ideally between 12 and 28 weeks (optimally before 16 weeks) and continued until

delivery.¹⁰ Low-dose aspirin prophylaxis should be considered for women with more than one of several moderate risk factors for preeclampsia. Risk factors include prior preeclampsia, chronic hypertension, pregestational diabetes, maternal BMI >30 kg/m², antiphospholipid syndrome and receipt of assisted reproduction.^{9,10}

Preeclampsia requires intensive monitoring and specific care. Eclampsia is a medical emergency, and therefore the goal of monitoring and treatment is to avoid this potentially fatal complication.

Table 1: Clinical risk assessment for preeclampsia*⁷

Risk Level	Risk Factors	Recommendation
High**	<ul style="list-style-type: none"> History of preeclampsia, especially when accompanied by an adverse outcome Multifetal gestation Chronic Hypertension Type 1 or 2 diabetes Renal disease Autoimmune disease (systemic lupus erythematosus or antiphospholipid syndrome) 	Recommend low-dose aspirin if the patient has one or more of these high-risk factors
Moderate***	<ul style="list-style-type: none"> Nulliparity Obesity (BMI > 30 kg/m²) Family history of preeclampsia (mother or sister) Sociodemographic characteristics (African American race, low socioeconomic status) Age 35 years or older Personal history factors (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, more than 10-year pregnancy interval) 	Consider low-dose aspirin if the patient has more than one of these moderate-risk factors****
Low	<ul style="list-style-type: none"> Previous uncomplicated full-term delivery 	Do not recommend low-dose aspirin

*Includes only risk factors that can be obtained from the patient’s medical history. Clinical measures, such as uterine artery Doppler ultrasonography, are not included.

**Single risk factors that are consistently associated with the greatest risk of preeclampsia. The preeclampsia incidence rate would be approximately 8% or more in a pregnant woman with one or more of these risk factors.

***A combination of multiple moderate-risk factors may be used by clinicians to identify women at high risk of preeclampsia. These risk factors are independently associated with moderate risk of preeclampsia, some more consistently than others.

****Moderate-risk factors vary in their association with increased risk of preeclampsia.

*Adapted from Committee on Practice Bulletins. The American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia. *Obstetrics and Gynecology* 2020;135:e237-260.

The prophylactic use of low-dose aspirin starting in early pregnancy can potentially reduce the rate of preeclampsia by up to 40%.¹²⁻¹⁴ The National Institute for Health and Clinical Excellence (NICE) has recommended that (a) all pregnant women should be screened in the first trimester for the risk of preeclampsia, and (b) pregnant women at high risk for preeclampsia should be treated with aspirin.¹⁵⁻¹⁷

Central Blood Pressure and Hypertension

Management of hypertension through cuff measurement of peripheral (brachial artery) pressures, which has been in use since the 1800's, has dramatically but incompletely improved the ability of health care providers and their patients to control hypertension and reduce associated end-organ damage. Multiple issues likely contribute to the ongoing socioeconomic burden of hypertension, including hypertensive disorders of pregnancy, despite the availability of multiple effective medications and widespread educational efforts. Such issues include, but are not limited to, case finding (early diagnosis), continuity and continued follow-up of care, affordability of care, medication adverse effects, medication compliance and challenges in modifying lifestyle behavior.

An underappreciated but clinically relevant area to consider is the precision and reliability of current monitoring, which is based on brachial blood pressure measurements, including patient and health care provider factors. In general, cuff brachial BP might be viewed as a surrogate for central (i.e., aortic) blood pressures; however, differences exist between brachial and aortic pressures and the differences can vary among different individuals.¹⁸⁻²⁰ Aortic pressure represents the actual pressure that is transmitted to organs affected by hypertension (e.g., heart, brain, kidney) due to the closer proximity of the ascending aorta to these vital organs. Non-invasive pulse wave analysis (PWA) is a technique that is based on transformation of the peripheral (brachial) arterial pressure waveforms into central aortic pressures waveforms including the following parameters:

- Central aortic systolic and diastolic BPs
- Augmentation index (ratio expressing the relationship of forward and backward traveling waves in the central aorta)
- Central aortic pulse pressure (systolic minus diastolic BP).
- Pulse pressure amplification (the ratio of peripheral to central pulse pressure)

Peripheral (brachial) BPs highly correlate with central BPs; however, significant variability exists such that central BPs cannot be reliably inferred from brachial pressures. Additionally, brachial systolic BPs are generally higher than central aortic BPs although diastolic BPs are similar. The ability to obtain and quantify these variables provide in-depth understanding of the vascular physiology and help determine risk and potential treatment strategies.

Cuff brachial blood pressure might be viewed as a surrogate for central (i.e., aortic) blood pressures; however, aortic pressure, which differs from brachial pressure, represents the actual pressure that is transmitted to organs affected by hypertension (e.g., heart, brain, kidney) due to the closer proximity of the ascending aorta to these vital organs.

The technology for non-invasive assessment of central aortic pressures through PWA is currently available and approved by the United States Food and Drug Administration (FDA). In recognition of the clinical utility of PWA, a Current Procedural Terminology (CPT) code has been established. The SphygmoCor XCEL system is a dual arterial pressure monitoring medical device measuring both brachial BPs and central aortic pressures (using partial cuff inflation to record the outgoing brachial waveform), which can be obtained in the clinic at the same time. The SphygmoCor XCEL is the only FDA cleared medical device for non-invasive central arterial pressure waveform measurement and analysis for all adults. The incorporation of PWA in the SphygmoCor System was developed to help guide treatment decisions designed to prevent or reduce long-term target organ damage and cardiovascular events resulting from increased aortic pressure.

The SphygmoCor XCEL system is a dual arterial pressure monitoring medical device for the measurement of brachial and central aortic pressures, which can be obtained in the clinic at the same time. The SphygmoCor XCEL is the only FDA cleared medical device for non-invasive central arterial pressure waveform measurement and analysis for all adults.

Non-invasive Central Aortic Pressure Predicts Preeclampsia

Early recognition of gestational hypertension and those at risk for preeclampsia represents a clinically important management objective for pregnant women. Identification of those at-risk permits focusing of resources where the need is greatest in the population of pregnant woman and for the developing fetus. Unlike the vast majority of patients with chronic hypertension, where end-organ damage develops over years to decades and acute events have been preceded by the gradual damage to the organ over time, pregnancy is a relatively short period where dramatic physiologic changes occur. The effects of preeclampsia and eclampsia can be acute and life-threatening to both the woman and the fetus. Therefore, tools that can identify those at risk and assist in management of gestational hypertension are necessary. Brachial BP monitoring remains a key tool, but non-invasive central aortic pressure monitoring can provide additional data that augment current management approaches. The following paragraphs describe data supporting the incorporation of central blood pressure monitoring into standard screening and for enhanced monitoring for women at risk for preeclampsia.

In a prospective screening study, Khalil and colleagues (2009) investigated whether pulse wave analysis (PWA) performed during the first trimester can predict preeclampsia in 210 low-risk women.²¹ Fourteen (6.7%) women developed preeclampsia. Eight of the 14 women developed preeclampsia before 34 weeks of gestation (early-onset preeclampsia). Augmentation Index (AIx) adjusted to a heart rate of 75 beats/minute (AIx-75) had a detection rate of 79% for all cases of preeclampsia and 88% for early-onset preeclampsia, while the mean brachial blood pressure was not predictive of preeclampsia. The false positive rate was 11%. A study of 32 women with gestational hypertension documented that central aortic systolic pressure and AIx appeared to be more predictive of the subsequent development of preeclampsia relative to brachial pressures.²²

Augmentation Index adjusted to a heart rate of 75 beats/minute (AIx-75) had a detection rate of 79% for all cases of preeclampsia and 88% for early-onset preeclampsia.

In another publication from the same group, the predictive value of the combination of first-trimester serum placental protein 13 (PP13), uterine artery Doppler pulsatility index (PI) and Alx-75 was evaluated.²³ They also evaluated concurrent and contingent strategies using combinations of the above tests for assessing the risk of preeclampsia in high-risk women. A nested case-control study design was used. For each case of preeclampsia (n=42), five matched controls were randomly selected. Compared with controls, women who developed preeclampsia had lower PP13, higher uterine artery mean PI and higher Alx-75 ($p < 0.001$). The highest detection rate for preeclampsia (85.7%; 95% CI, 71.5-94.6%) and preeclampsia requiring delivery before 34 weeks (92.9%; 95% CI, 66.1-99.8%) was achieved by concurrent testing with all three markers. The false positive rate was 10%. The best contingency screening sequences for preeclampsia were (Alx-75 → PP13 → mean PI) and (PP13 → Alx-75 → mean PI), with an 86% detection rate with false-positive rates of 9 and 10%, respectively. In summary, the combination of first trimester PP13, uterine artery mean PI and pulse wave analysis can be useful for the prediction of preeclampsia in women at increased a-priori risk and may be useful in clinical practice.

A report in 2012 evaluated the potential value of assessment of central aortic systolic BP (cSBP), pulse wave velocity (PWV) and Alx at 11-13 weeks gestation in identifying women who subsequently develop preeclampsia.²⁴ Maternal history and characteristics were recorded and PWV, Alx-75 and cSBP measured. Women who developed preeclampsia (n=181) were compared to unaffected controls (n=6,766), wherein the preeclampsia group had an increase in Alx-75 ($p < 0.0001$), PWV ($p < 0.0001$) and cSBP ($p < 0.0001$). cSBP had the highest predictive value for preeclampsia. It was particularly notable that in the group with chronic hypertension, in those who developed preeclampsia, compared to those who did not, the cSBP (1.29 vs. 1.15 multiples of the median of the control group (MoM); $p = 0.001$) was increased but there was no significant difference in PWV (1.02 vs. 1.00 MoM; $p = 0.921$) or Alx-75 (1.37 vs. 1.21 MoM; $p = 0.104$). The authors concluded that compared with women who remain normotensive, women who develop preeclampsia have higher cSBP and arterial stiffness (as measured by PWV and Alx-75), which is apparent from the first trimester of pregnancy.

Compared with women who remain normotensive, women who develop pre-eclampsia have higher cSBP, PWV and Alx-75, which is apparent from the first trimester of pregnancy.

A report by Anvi and colleagues sought to examine whether PWA could discriminate between normal and hypertensive pregnancies.²⁵ One hundred pregnant women were studied: five with severe preeclampsia, 27 with gestational hypertension, 14 with chronic hypertension and 54 with normal pregnancy. Augmentation pressure, Alx and Alx-75 were significantly higher in women with gestational hypertension and preeclampsia compared with normal pregnancies and women with chronic hypertension ($p < 0.05$ for all). There were no significant differences between normal pregnancies and women with chronic hypertension ($p > 0.05$ for all comparisons). Alx and augmentation pressure were significantly different among groups even after adjusting for peripheral BP. The study provides further support to the utility of adding measurement of central aortic pressures to standard brachial blood pressure measurements.

Marozio and colleagues examined the possible correlation between pulse wave analysis (PWA) parameters measured during the first trimester of pregnancy in normotensive, low-risk women, and the development of hypertensive disorders later in pregnancy.²⁶ The study population (n=1,648) was recruited at the time of prenatal screening for chromosomal abnormalities (11+0 to 12+6 weeks of gestation). The values of central

aortic systolic pressure, central aortic diastolic pressure, central aortic mean pressure, central aortic pulse pressure, and Alx-75 measured in the first trimester of pregnancy were significantly higher in the women who later developed hypertensive disorders of pregnancy than in those who remained normotensive ($p < 0.0001$ for all except for aortic pulse pressure ($p = 0.014$)). The aortic systolic pressure (sensitivity 72.6%; specificity 59.6%) was found to be the best predictor for the later development of hypertension.

Table 2: Predictive values of PWA parameters recorded at 11 – 13 weeks gestation in relation to later development of hypertensive disorders of pregnancy*

Variable	Sensitivity (95% CI)	Specificity (95% CI)	AUC (95% CI)
aortic systolic pressure	72.6 (62.5, 81.3)	59.6 (55.7, 62.1)	0.70 (0.68, 0.72)
aortic diastolic pressure	55.2 (44.7, 65.4)	77.6 (75.5, 79.7)	0.68 (0.66, 0.70)
aortic mean pressure	65.6 (55.2, 75.0)	67.3 (64.9, 69.7)	0.70 (0.68, 0.72)
aortic pulse pressure	63.5 (53.1, 73.1)	51.0 (48.5, 53.5)	0.58 (0.55, 0.60)
Alx-75	56.3 (45.8, 66.6)	64.5 (62.0, 66.9)	0.62 (0.60, 0.64)
Mean Ut-PI	42.2 (34.2, 50.6)	65.9 (63.9, 67.9)	0.54 (0.52, 0.56)

AUC = area under the curve, Ut-PI = uterine artery pulsatility index

*Adapted from Marozio et al Arterial stiffness in normal pregnancy at 11-13 weeks of gestation and risk of late-onset hypertensive disorders of pregnancy. J Hypertension 2019;37:1018-22.

Brachial BP was not predictive of the subsequent development of hypertensive disorders of pregnancy, which is consistent with the view that, while correlated, brachial BP and central aortic BP are not interchangeable. The incidence of preterm hypertensive disorders of pregnancy, particularly of preterm, early-onset preeclampsia, was too low to allow subgroup analysis of the predictive performance of PWA parameters. The authors concluded that in normotensive, low-risk pregnant women, PWA may be useful for the early detection of risk for the development of hypertensive disorders of pregnancy and may allow for targeted surveillance and preventive intervention.

Aortic systolic pressure was found to be the best predictor for the later development of hypertension. Brachial BP was not predictive of the subsequent development of hypertensive disorders of pregnancy, which is consistent with the view that, while correlated, brachial BP and central aortic BP are not interchangeable.

A prospective longitudinal study of hemodynamics in 245 women at risk of preeclampsia documented that elevation in systolic aortic pressure is associated with the development of pre-term preeclampsia and may occur in women who are normotensive early in pregnancy.

Hausvater and colleagues conducted a systematic review and meta-analysis to investigate the association between preeclampsia and arterial stiffness as measured by PWA and pulse wave velocity (PWV).²⁷ Twenty-three relevant studies were included. A significant increase in all arterial stiffness indices combined was observed in women with preeclampsia compared to women with normotensive pregnancies [standardized mean difference 1.62, 95% confidence interval (CI) 0.73-2.50]. In particular, preeclampsia was significantly

associated with a 1.04 m/s increase in carotid-femoral PWV and a 15.1% increase in Alx. On the other hand, carotid-radial PWV increase did not reach significance. Significant increases in arterial stiffness measurements were noted in women with preeclampsia compared with those with gestational hypertension. The data indicate that arterial stiffness measurements may be useful in detecting preeclampsia and may play a role in the increased risk of future cardiovascular complications seen in women with a history of preeclampsia.

A separate systematic review and meta-analysis of published literature examined whether PWA and PWV measurements during pregnancy differed between healthy patients and patients with placental-mediated diseases including preeclampsia, small for gestational age, fetal death, and placental abruption.²⁸ A total of 2,806 citations and 36 studies were reviewed. Nine studies (n=15,923) were selected for further quantitative assessment. Compared with healthy pregnancy, measures from PWA and PWV that reflected arterial stiffness were consistently increased among pregnant women who subsequently developed preeclampsia during all trimesters. In the first trimester, mean Alx-75 (%) in the preeclampsia group was significantly higher with estimated standardized mean difference of 0.90 [95% confidence intervals (95% CI) 0.07-1.73; p=0.034]. In the second trimester, the preeclampsia group had significantly higher PWV (m/s) with estimated standardized mean difference of 1.26 (95% CI 0.22-2.30; p=0.018). Concerning the small for gestational age group, mean (SD) Alx (%) was greater during the second trimester only (65.5 (15.6) vs. 57.0 (11.2), p<0.01).

Table 3: Estimated standardized mean difference and corresponding 95% confidence intervals (lower, upper) between the preeclampsia and healthy groups for arterial stiffness measurements (pulse wave velocity, augmentation index, augmentation index 75) at three trimesters.

Parameter	First Trimester	Second Trimester	Third Trimester
PWV (m/s)	0.85 (-1.07, 2.78)	1.26 (0.22, 2.30) ¹	0.49 (0.20, 0.78) ²
Alx (%)	0.38 (-0.18, 0.93)	0.19 (-0.06, 0.44)	0.48 (0.20, 0.77) ³
Alx-75 (%)	0.90 (0.07, 1.73) ⁴	0.05 (-0.46, 0.56)	No study

¹p=0.018, ²p<0.001, ³p=0.001, ⁴p=0.034

*Adapted from Osman et al. Association between arterial stiffness and wave reflection with subsequent development of placental-mediated diseases during pregnancy: Findings of a systematic review and meta-analysis. *J Hypertension* 2018;36:1005-14.

The analyses indicate that there is significant increase in arterial stiffness as assessed by PWA and PWV among pregnant women who subsequently developed preeclampsia and small for gestational age fetuses and are consistent with considering a role for central aortic pressure evaluation during pregnancy.

Incorporating Central Aortic Pressure Assessment into Prenatal Care

Incorporation of non-invasive measurements of central aortic pressures can improve hypertension management in the following areas:

- Refine monitoring requirements.
- Reduce over-treatment.
- Improve under-treatment.
- Reduce costs of management (e.g., medication costs, monitoring such as ambulatory blood pressure monitoring (ABPM)).

Optimizing prescription medication and the self-administration of therapy is critical to controlling gestational hypertension.

The data from multiple publications indicate that central aortic PWA can be used to identify pregnant women at risk for preeclampsia. Expert consensus statements have documented and recommended that risk factor identification for gestational hypertension and preeclampsia be part of prenatal care.¹¹ In fact, the US Preventive Services Task Force has recommended that pregnant women be screened for preeclampsia.²⁹ Based on the current evidence, PWA should be considered as part of standard care given that increases in AIx-75 and central aortic systolic pressure (cSBP) are risk factors that can be identified in the first trimester. cSBP appears to provide complimentary data to that of brachial systolic BP (i.e., the tests are not redundant or interchangeable). The identification of elevated PWA variables should therefore warrant consideration of enhanced monitoring as they appear to indicate increased risk for preeclampsia (e.g., enhanced monitoring – office and home-based) and preventive therapeutic decisions (e.g., prescription of low-dose aspirin).

Related issues that provide compelling examples of the need to incorporate PWA into prenatal care include the problem of white-coat hypertension, direct and indirect medication adverse effects in the case of over-treatment (i.e., symptoms that lead to medication discontinuation, morbidity such as hypotension, metabolic effects, and organ adverse effects). PWA is an additional tool that can be seamlessly adapted to the current cuff brachial blood pressure monitoring paradigm.

Incorporation of central aortic PWA into the treatment paradigm for gestational hypertension has the following advantages:

1. Confirmation of hypertension so that initiation of medication is more likely to be the appropriate decision for a patient.
Scenario: Concurrent elevation in brachial and central pressures
2. Avoiding initiation of medication when white coat hypertension is suspected.
Scenario: Elevated brachial pressure and normal central pressures, provided that an elevated heart rate does not confound the results.
3. Confirmation that increased treatment may not be needed.
Scenario: Borderline high peripheral pressures and normal central pressures
4. Targeting when to consider reduction of medication.
Scenario: Normal peripheral and low central pressures, or extended period of normal peripheral and normal central pressures (particularly in the setting of medication tolerance issues)

The publications and data described in the previous sections indicate that the adjunctive measurement of central pressures provides clinically important patient care information. The provision of both peripheral and central pressures can occur during the same office visit, is available within a dual arterial pressure monitoring device (SphygmoCor XCEL), is clinically appropriate, and a cost-effective approach to identifying risk for preeclampsia and managing gestational hypertension.

Summary and Conclusions

The following is a summary of the key discussion points:

- Hypertensive disorders of pregnancy occur in 1 in every 12 to 17 pregnancies. Approximately 25% of cases

of gestational hypertension progress to preeclampsia. Proactive identification of populations at risk of preeclampsia is a necessary part of pregnancy management.

- Central aortic systolic pressure is highly correlated to brachial systolic pressures; however, central systolic pressures cannot be reliably inferred from brachial pressures.
- Elevated central aortic pressure predicts preeclampsia. Elevated central aortic pressure appears to be more sensitive in assessing the risk of preeclampsia compared to brachial pressure. Brachial and central aortic pressures provide complimentary information for risk prediction and management decisions.
- Measurements of central arterial pressures can be incorporated into the current approaches to hypertensive disorders of pregnancy as the dual arterial pressure SphygmoCor XCEL device, the only FDA cleared medical device for non-invasive central arterial pressure waveform measurement and analysis for all adults, can provide both brachial and central aortic pressures at the same time.
- Incorporation of central aortic PWA into the treatment paradigm for hypertension has the following advantages:
 - Confirmation of hypertension so that initiation of medication is more likely to be the appropriate decision for a patient.
Scenario: Concurrent elevation in brachial and central pressures
 - Avoiding initiation of medication when white coat hypertension is suspected.
Scenario: Elevated brachial pressure and normal central pressures
 - Confirmation that increased treatment may not be needed.
Scenario: Borderline high peripheral pressures and normal central pressures
 - Targeting when to consider reduction of medication.
Scenario: Normal peripheral and low central pressures, or extended period of normal peripheral and normal central pressures (particularly in the setting of medication tolerance issues)

In conclusion, based on current technology, the availability of a non-invasive dual arterial pressure measurement system, the compelling clinical rationale and the clinical published research, incorporation of central aortic pressure should be a part of the care of all pregnant women.

References

1. Bateman BT, Shaw KM, Kuklina EV, Callaghan WM, Seely EW, Hernandez-Diaz S. Hypertension in women of reproductive age in the United States: NHANES 1999-2008. *PLoS ONE*. 2012;7(4):e36171.
2. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013;122(5):1122-31.
3. S. Preventive Services Task Force. Screening for preeclampsia: U.S. Preventive Services Task Force recommendation statement. *JAMA*. 2017;317:1661-67.
4. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. *Circ Research* 2019;124:1094-1112.
5. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ* 2007;335:974; doi:10.1136/bmj.39335.385301.BE.
6. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidaset MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. *Hypertension* 2009;53:944-51.
7. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. *Am Heart J* 2008;156:918-30.

8. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. *Hypertension* 2010;56:166-71.
9. Brown MA, Magee LA, Kenny LC, Karumanchi A, McCarthy FP, et al. Hypertensive disorders of pregnancy. Classification, diagnosis, and management recommendations for international practice. *Hypertension* 2018;72:24-43.
10. American College and Obstetricians and Gynecologists. Low dose aspirin use during pregnancy. <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/07/low-dose-aspirin-use-during-pregnancy>. Accessed June 7, 2021.
11. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. <https://www.nice.org.uk/guidance/ng133/chapter/recommendations#:~:text=2%20Advise%20pregnant%20women%20at,disease%20during%20a%20previous%20pregnancy>. Accessed June 7, 2021.
12. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. *N Engl J Med*. 2017;377:613-22.
13. Hoffman MK, Goudar SS, Kodkany BS, et al; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;395:285-93.
14. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. *Am J Obstet Gynecol*. 2017;216:121-8.e2.
15. Committee on Practice Bulletins. The American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia. *Obstetrics and Gynecology* 2020;135:e237-260.
16. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol*. 2020;135:e237-60.
17. Brown MA, Magee LA, Kenny LC, et al; International Society for the Study of Hypertension in Pregnancy (ISSHP). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertens*. 2018;13:291-310.
18. Pauca A, O'Rourke MF, Kon N. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. *Hypertension*. 2001;38:932-937
19. McEnery CM, Yasmin, McDonnell B, Munnery M, Wallace S, Rowe C, Cockcroft JR, Wilkinson IB, on Behalf of the Anglo-Cardiff Collaborative Trial Investigators. Central pressure: variability and impact of cardiovascular risk factors. The Anglo-Cardiff Collaborative Trial II. *Hypertension*. 2008;51:1476-1482.
20. McEnery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. *European Heart Journal* (2014) 35, 1719-1725
21. Khalil AA, Cooper DJ, Harrington KF. Pulse wave analysis: a preliminary study of a novel technique for the prediction of preeclampsia. *BJOG* 2009; 116:268-276.
22. Khalil A, Jauniaux E, Harrington KF. Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. *Obstetrics and Gynecology* 2009;113:646-54.
23. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First-trimester markers for the prediction of preeclampsia in women with a-priori high risk. *Ultrasound Obstet Gynecol* 2010; 35:671-679.
24. Khalil A, Akolekar R, Syngelaki A, Elkhoul M, Nicolaides KH. Maternal hemodynamics in normal pregnancies at 11-13 weeks' gestation. *Fetal Diagn Ther* 2012; 32:179-185.
25. Avni B., Frenkel G., Shahar L., Golik A., Sherman D., Dishy V. Aortic stiffness in normal and hypertensive pregnancy. *Blood Pressure* 2010;19:11-15.
26. Marozio L, Chiarle G, Filippini C, Challancin S, Tancredi A, Viora E, Benedetto C. Arterial stiffness in normal pregnancy at 11-13 weeks of gestation and risk of late-onset hypertensive disorders of pregnancy. *J Hypertension* 2019;37:1018-22.
27. Hausvater A, Giannone T, Gomez Sandoval YH, Doonan RJ, Antonopoulos CN, Matsoukas IL, Petridou ET, Daskalopoulou SS. The association between preeclampsia and arterial stiffness. *J Hypertension* 2012;31:17-33.
28. Osman MW, Nath M, Breslin E, Khalil A, Webb DR, Robinson TG, Mousa HA. Association between arterial stiffness and wave reflection with subsequent development of placental-mediated diseases during pregnancy: Findings of a systematic review and meta-analysis. *J Hypertension* 2018;36:1005-14.
29. Bibbins-Domingo K, Grossman DC, et al. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2017;317:1661-7.

Contact us at: info@atcormedical.com
www.atcormedical.com

ATCOR 

“The Gold Standard” in
 Central Blood Pressure Analysis